Show simple item record

dc.contributor.authorSimcock, Peteren
dc.contributor.authorKingett, B.en
dc.contributor.authorMann, N.en
dc.contributor.authorReddy, V.en
dc.contributor.authorPark, J.en
dc.date.accessioned2016-01-19T12:35:28Zen
dc.date.available2016-01-19T12:35:28Zen
dc.date.issued2014-10-01en
dc.identifier.citationEye (Lond). 2014 Oct;28(10):1161-4.en
dc.identifier.issn1476-5454en
dc.identifier.pmid25033899en
dc.identifier.doi10.1038/eye.2014.153en
dc.identifier.urihttp://hdl.handle.net/11287/593828en
dc.description.abstractPURPOSE: To evaluate the safety of a nurse practitioner (NP)-delivered injection service for the treatment of wet age-related macular degeneration (wAMD) with ranibizumab. METHODS: An evaluation of medical staffing resources for providing an injection service for wAMD highlighted difficulties covering lists. An alternative strategy of an NP-delivered injection service was evaluated. Two suitable NPs with previous extensive experience in minor surgical procedures were identified. The department's senior vitreo-retinal consultant supervised the NP's training programme. A prospective safety audit was conducted for the first 5.5 years of the service. RESULTS: The NPs administered 10 006 injections in the first 5.5 years of the service (1 May 2008 to 8 October 2013). This represented 84.1% of the total injections performed during this period. Four patients developed presumed infectious endophthalmitis (1 was culture positive and 3 were culture negative). The incidence of post-injection endophthalmitis was 0.04%. There was no evidence of lens touch, retinal detachment, or systemic thrombo-embolic events. CONCLUSIONS: Carefully selected and well-trained NPs are capable of delivering a safe and effective wAMD injection treatment service. This work demonstrates how such a service can be established and provides safety data that other units can use as a benchmark when evaluating their own practice.en
dc.language.isoengen
dc.publisherNatureen
dc.relation.urlhttp://dx.doi.org/10.1038/eye.2014.153en
dc.titleA safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitionersen
dc.typeJournal Articleen
dc.identifier.journalEyeen
dc.description.noteThis article is available via Open Access. Please click on the 'Additional Link' above to access the full-text.en


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record